SELLASClinical Trials•globenewswire•
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
Sentiment:Positive (70)
Summary
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire